Genocea Biosciences is a clinical-stage biotechnology company focused on the discovery and development of T-cell vaccines for infectious diseases and cancer. The company leverages a deep understanding of cellular immunity to identify and prioritize antigens that stimulate robust T-cell responses, addressing areas of high unmet medical need.
At the core of Genocea’s research platform is ATLAS, a proprietary technology that profiles patient T-cell responses against a broad array of potential antigens. By mapping how immune cells recognize disease-relevant targets, ATLAS enables the selection of candidates with the greatest likelihood of efficacy and supports both therapeutic and prophylactic vaccine design.
Founded in 2011 as a spin-out from Harvard Medical School, Genocea has advanced its lead program, GEN-003, through Phase II clinical trials for recurrent genital herpes, demonstrating favorable safety and immunogenicity profiles. The company continues to apply lessons learned from this work to additional infectious disease and oncology targets, moving promising candidates toward human studies.
Headquartered in Cambridge, Massachusetts, Genocea brings together a leadership team with extensive experience in immunology, clinical development and biopharmaceutical strategy. The company collaborates with academic institutions and industry partners to broaden its pipeline and expand the global reach of its vaccine candidates.
AI Generated. May Contain Errors.
Free GNCAQ Stock Alerts